JINGXIN(SZ:002020)2022-08-25 16:00Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.87 billion, representing an increase of 8.46% compared to the same period last year[22]. - Net profit attributable to shareholders was approximately ¥274.93 million, an increase of 15.68% year-on-year[22]. - The net cash flow from operating activities reached approximately ¥274.03 million, a significant increase of 306.81% compared to the previous year[22]. - Total assets at the end of the reporting period were approximately ¥6.71 billion, reflecting a growth of 1.33% from the end of the previous year[22]. - The net assets attributable to shareholders decreased by 3.41% to approximately ¥4.79 billion compared to the end of the previous year[22]. - Basic and diluted earnings per share remained stable at ¥0.35, unchanged from the previous year[22]. - The weighted average return on equity was 6.09%, down by 0.79 percentage points compared to the previous year[22]. - The company reported non-recurring gains and losses amounting to approximately ¥22.12 million, primarily from government subsidies and asset disposals[29]. - The company achieved operating revenue of 1.873 billion yuan, a year-on-year increase of 8.46%[59]. - The company's net profit attributable to shareholders reached 297 million yuan, up 6.19% year-on-year, while the net profit after deducting non-recurring gains and losses was 275 million yuan, an increase of 15.68%[59]. - The medical device segment reported revenue of 297 million yuan, reflecting a significant year-on-year growth of 19.10%[59]. Market and Product Development - The company is focused on expanding its market presence and developing new products and technologies to drive future growth[33]. - The product structure has been continuously optimized, with stable growth in the profitability of main businesses, including cardiovascular drugs and CNS drugs, with key products like Levetiracetam tablets ranking first in the national hospital market[46]. - The company has a rich product pipeline covering CNS, cardiovascular, and digestive systems, with over 10 innovative drug projects in progress[48]. - The company aims to become a leader in the CNS and cardiovascular fields, continuously enhancing its core competitiveness through innovation and collaboration[46]. - The company has established a comprehensive marketing network covering commercial channels, retail pharmacies, and hospitals, enhancing its brand recognition and market influence[53]. - The e-commerce sales channel grew rapidly, achieving revenue of 78.48 million yuan, a remarkable year-on-year increase of 370%[64]. - The company is actively developing new medical display technologies and has entered into strategic partnerships with major players like Siemens and Fujifilm[65]. Research and Development - The company holds a total of 204 patents, including 149 invention patents, showcasing its strong R&D capabilities[52]. - The company plans to establish a new R&D platform in Hangzhou focusing on biopharmaceuticals and medical devices, further enhancing its innovation capabilities[52]. - The R&D investment for the reporting period was ¥170,157,604.98, reflecting a 7.94% increase from ¥157,644,108.74 in the previous year[76]. - The company has submitted a drug registration application for the innovative drug EVT201, which, if approved, will enhance its competitiveness in the mental health sector[71]. - The company is focused on building a research team that aligns with its innovative transformation goals to enhance its competitive edge in the pharmaceutical industry[110]. Operational Efficiency - The pharmaceutical manufacturing segment generated ¥1,572,666,202.34 in revenue, accounting for 83.98% of total revenue, with a year-on-year growth of 6.74%[79]. - The company has implemented 84 lean management projects in drug manufacturing, resulting in an 8.3% increase in per capita production efficiency[69]. - The company has adopted a procurement model combining centralized procurement and subsidiary self-procurement to ensure quality and cost control[38]. - The production model is based on sales forecasts, maintaining appropriate safety stock, and customized production for EU exports[39]. - The company has signed strategic cooperation agreements with key suppliers to ensure the continuity and stability of the supply chain[38]. Environmental and Social Responsibility - Environmental regulations are becoming stricter, and the company is committed to sustainable development by adhering to higher environmental standards in its manufacturing processes[110]. - The company has established a comprehensive wastewater treatment system with a daily processing capacity of 1,600 tons, ensuring compliance with discharge standards[126]. - The company has constructed two standard solid waste storage facilities covering an area of approximately 1,800 m² for hazardous waste disposal[126]. - The company has implemented a multi-level condensation and RTO system for treating process waste gases, achieving compliance with emission standards[131]. - The company has invested 10 million yuan to establish a rural revitalization and poverty alleviation fund in collaboration with local enterprises[142]. - The company has successfully passed 13 environmental impact assessments since 2004, demonstrating its commitment to environmental compliance[134]. - The company has installed online monitoring equipment for key wastewater discharge parameters, ensuring real-time compliance tracking[132]. - The company has developed emergency response plans for environmental incidents, enhancing its management capabilities[137]. - The company has achieved stable operation of pollution control facilities, with no reported environmental pollution incidents[130]. - The company has adopted innovative management practices and technological advancements to promote clean production and pollution prevention[131]. Corporate Governance and Shareholder Information - The company has committed to avoid related party transactions with Jingxin Pharmaceutical and Shenzhen Jufeng, ensuring fair pricing and compliance with legal requirements[146]. - The company has pledged that the funds raised from the non-public offering of A-shares in 2020 will be used specifically for project construction and will not be diverted for other purposes[148]. - The company reported no significant litigation or arbitration matters during the reporting period[155]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[151]. - The company has established a special account to manage the funds raised from the non-public offering, ensuring proper usage[148]. - The company has confirmed that all commitments made during the IPO and refinancing processes are being fulfilled normally[148]. - The company has not reported any major related party transactions during the reporting period[157]. - The largest shareholder, Lü Gang, holds 19.75% of the shares, totaling 178,796,755 shares[186]. - The second largest shareholder, Jingxin Holdings Group Co., Ltd., owns 14.91% of the shares, amounting to 134,966,393 shares[190]. - The company has a total of 44,289,798 shares in its repurchase account, representing 4.89% of the total share capital[190]. - There were no changes in the shareholding of directors, supervisors, and senior management during the reporting period[195]. - The controlling shareholder and actual controller of the company did not change during the reporting period[196]. - The company does not have any preferred shares in the reporting period[200].